Ichnos Glenmark Innovation

Ichnos Glenmark Innovation (IGI) is an alliance between Ichnos Sciences, a global fully integrated clinical-stage biotechnology company developing Multispecifics in oncology, and Glenmark Pharmaceuticals, an integrated research-led global pharmaceutical company. Headquartered in New York, IGI is advancing a pipeline led by ISB 2001, a first-in-class trispecific T-cell engager. The corporate overview describes IGI as combining forces to transform oncology, one molecule at a time.

IGI develops novel multispecific antibodies for hematological malignancies and solid tumors using its proprietary BEAT technology platform. Its three centers of innovation in the United States, Switzerland, and India support discovery through clinical development. Leadership describes a highly experienced management team with more than 120 years of combined experience.